Recently, Shanghai Easy-Flow Medical Tech Co., Ltd. ( "Easy-Flow™") has successfully completed its Series A+ financing by raising over CNY 100 million. 

This round was led by Shanghai Healthcare Capital, a subsidiary of Shanghai Industrial Investment (Holdings) Co., Ltd (SIIC), Xingzheng Capital participated 

as a co-investor, while existing investors Legend Capital and HJ Partners provided follow-on investment. The fresh capital will primarily support pre-market 

clinical trials and registration applications for the innovative products, and market expansion both domestically and internationally.

Easy-Flow™ has developed a comprehensive product portfolio that spans interventional treatment of lower limb arterial stenosis, thrombosis management, 

venous disease intervention, and chronic disease management. To date, Easy-Flow™has obtained seven medical device registration certificates, three products 

have completed pre-market clinical trials and have entered the registration approval process, while several others initiating CE mark application processes. 

Additionally, EF-Lumber^® Peripheral Drug-Eluting stent has entered NMPA Special Review Procedures for Innovative Medical Devices in March 2025. Since 

the NMPA approval of its first product, EF-Rhine^® Constrained PTA Dilatation Balloon Catheter, in December 2023, Easy-Flow™ has rapidly advanced its 

commercialization efforts in China.

Mr. Liang Weibin, partner of Shanghai Healthcare Capital stated: "We consistently focus on opportunities in the innovative medical device sector.The penetration 

rate of peripheral vascular interventions remains relatively low, yet the peripheral vascular device market presents strong clinical demand and high growth potential, 

companies with strong product capabilities and diversified portfolios are well positioned to capture market opportunities and gain significant market share. 

Easy-Flow™is committed to delivering comprehensive peripheral solutions, standing out in the interventional field that combines innovative products with efficient 

execution. Since its establishment, the company has accelerated multiple product launches into clinical trials and market approval, continuing to demonstrate 

exceptional commercialization capabilities. We believe Ms. Miao and her team can establish Easy-Flow™as a core player in China's innovative medical device industry, 

delivering product portfolios with superior efficacy and enhanced accessibility for patients nationwide."

Ms.Miao Zhenghua, Chairman and General Manager of Easy-Flow™, stated: "We sincerely appreciate the trust and support from Shanghai Healthcare Capital, 

Xingzheng Capital, and our long-term investors. This round of financing will accelerate the market access and commercialization of our core products in China, while 

also expediting our expansion into international market. We remain committed to strengthen quality control and improving product accessibility, while accurately 

capturing evolving clinical needs. Through a dual-market strategy encompassing both domestic and global markets, independent R&D and strategic partnerships, 

we are dedicated to continuously optimizing our commercialization capabilities to support long-term, high-quality development."